Assessment of Brain Natriuretic Peptide Serum Levels in Children with Chronic Kidney Disease

Chronic kidney disease (CKD) is a significant global public health issue,with a growing number of cases that could potentially approach epidemic proportions.(CKD) in both children and adults is linked to severe outcomes,such as higher chances of death,renal failure,cardiovascular disease,mineral bone problem,and inadequate nutrition.In patients with chronic kidney disease (CKD),both B-type natriuretic peptide (BNP) and its amino-terminal cleavage product,N-terminal pro-B-type natriuretic peptide (NT-pro-BNP),are widely recognized as biomarkers for diagnosing,predicting outcomes,and monitoring treatment in patients with heart-related conditions, particularly heart failure (HF).As the glomerular filtration rate (GFR) decreases,the levels of natriuretic peptides (NPs) tend to increase.Measuring blood BNP (or NT-pro-BNP) in children has become widely accepted as a valuable and dependable biomarker for diagnosing,managing, and perhaps predicting the outcome of major structural and functional cardiovascular disease (CVD). Subjects and Methods:This study is across-sectional case control study was conducted upon 60 children with chronic kidney disease collected from the Pediatric Department and Pediatric Outpatient Nephrology Clinic and Pediatric Unit of Dialysis–Minia University Children Hospital in a period from April 2020 to June and 30 apparently healthy children with age and sex matched with the CKD children 2022. All children were subjected to:detailed medical history,through examination,evaluation of serum BNP level, estimated GFR calculated from Schwartz formula. Results:Shows significantly increased the B-type natriuretic peptide (BNP) levels in both CKD groups compared with control. It also showed significant decrease after the dialysis effect in dialyzed CKD children. Conclusion:CKD children especially those on hemodialysis have higher levels of BNP,thus they at higher risk of cardiovascular disease.